Natera and Aveta Biomics partner on phase 3 head and neck cancer trial
Go back to Natera and Aveta Biomics partner on phase 3 head and neck cancer trial| (NASDAQ: NTRA) | Delayed: 264.69 +0.47 (0.18%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $264.22 | 52 Week High | $13.80 | |||
| Open | $264.22 | 52 Week Low | $6.52 | |||
| Day High | $273.00 | P/E | N/A | |||
| Day Low | $261.59 | EPS | $0.00 | |||
| Volume | 598,253 | |||||
